ascopubs.org

Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate ...

PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer. This is an ASCO ...
ascopubs.org

First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.

Using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer. A phase II study of anlotinib plus albumin-bound paclitaxel in patients with ...